JP2001502915A - 新規な幹細胞因子受容体アゴニストとしての環状に並べ替えたポリペプチド - Google Patents

新規な幹細胞因子受容体アゴニストとしての環状に並べ替えたポリペプチド

Info

Publication number
JP2001502915A
JP2001502915A JP10520526A JP52052698A JP2001502915A JP 2001502915 A JP2001502915 A JP 2001502915A JP 10520526 A JP10520526 A JP 10520526A JP 52052698 A JP52052698 A JP 52052698A JP 2001502915 A JP2001502915 A JP 2001502915A
Authority
JP
Japan
Prior art keywords
cells
seq
receptor agonist
stem cell
hematopoietic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP10520526A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001502915A5 (enExample
Inventor
ワーター，チャールズ，エイ． マック
フェン，イーキン
Original Assignee
ジー．ディー．サール アンド カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジー．ディー．サール アンド カンパニー filed Critical ジー．ディー．サール アンド カンパニー
Publication of JP2001502915A publication Critical patent/JP2001502915A/ja
Publication of JP2001502915A5 publication Critical patent/JP2001502915A5/ja
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP10520526A 1996-10-25 1997-10-23 新規な幹細胞因子受容体アゴニストとしての環状に並べ替えたポリペプチド Abandoned JP2001502915A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2916596P 1996-10-25 1996-10-25
US60/029,165 1996-10-25
PCT/US1997/018701 WO1998018924A1 (en) 1996-10-25 1997-10-23 Circularly permuted polypeptides as novel stem cell factor receptor agonists

Publications (2)

Publication Number Publication Date
JP2001502915A true JP2001502915A (ja) 2001-03-06
JP2001502915A5 JP2001502915A5 (enExample) 2005-06-16

Family

ID=21847588

Family Applications (1)

Application Number Title Priority Date Filing Date
JP10520526A Abandoned JP2001502915A (ja) 1996-10-25 1997-10-23 新規な幹細胞因子受容体アゴニストとしての環状に並べ替えたポリペプチド

Country Status (6)

Country Link
US (1) US5969105A (enExample)
EP (1) EP0941321A1 (enExample)
JP (1) JP2001502915A (enExample)
AU (1) AU734594B2 (enExample)
CA (1) CA2268023A1 (enExample)
WO (1) WO1998018924A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023145860A1 (ja) * 2022-01-27 2023-08-03 味の素株式会社 Ｓｃｆ受容体結合ペプチド

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207454B1 (en) 1989-10-16 2001-03-27 Amgen Inc. Method for enhancing the effciency of gene transfer with stem cell factor (SCF) polypeptide
US6852313B1 (en) 1989-10-16 2005-02-08 Amgen Inc. Method of stimulating growth of melanocyte cells by administering stem cell factor
US6248319B1 (en) 1989-10-16 2001-06-19 Krisztina M. Zsebo Method for increasing hematopoietic progenitor cells by stem cell factor polypeptides
US7144731B2 (en) 1989-10-16 2006-12-05 Amgen Inc. SCF antibody compositions and methods of using the same
US5581476A (en) 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
MXPA01005564A (es) * 1998-12-04 2003-07-14 Naval Medical Res Ct Celulas del endotelio cerebral humano en medio de crecimiento y metodo para expansion de celulas de tallo de medula osea cd34+cd38-nativas.
EP1228200A1 (en) * 1999-10-27 2002-08-07 California Institute Of Technology Production of functional hybrid genes and proteins
US6346247B1 (en) 1999-10-28 2002-02-12 Promega Corporation Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies
GB0024550D0 (enExample) 2000-10-06 2000-11-22 Oxford Biomedica Ltd
MXPA03005014A (es) 2000-12-06 2004-09-10 Robert J Hariri Metodo para recolectar celulas madres de la placenta.
US7311905B2 (en) 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
AU2002251935B2 (en) 2001-02-14 2007-11-29 Celularity Inc. Post-partum mammalian placenta, its use and placental stem cells therefrom
KR100961859B1 (ko) 2001-07-11 2010-06-09 맥시겐 홀딩스 엘티디 지-씨에스에프 접합체
AU2003298775B2 (en) 2002-11-26 2008-07-17 Anthrogenesis Corporation Cytotherapeutics, cytotherapeutic units and methods for treatments using them
KR20080027291A (ko) 2005-06-01 2008-03-26 맥시겐 홀딩스 엘티디 피이지화된 지-씨에스에프 폴리펩타이드 및 그 제조방법
EP1957633B1 (en) 2005-10-13 2013-12-18 Anthrogenesis Corporation Immunomodulation using placental stem cells
AU2006332679A1 (en) 2005-12-29 2007-07-12 Anthrogenesis Corporation Co-culture of placental stem cells and stem cells from a second source
KR20180105266A (ko) 2005-12-29 2018-09-27 안트로제네시스 코포레이션 태반 줄기 세포 집단
CN103356710A (zh) 2007-02-12 2013-10-23 人类起源公司 利用胎盘干细胞治疗炎性疾病
US9200253B1 (en) 2007-08-06 2015-12-01 Anthrogenesis Corporation Method of producing erythrocytes
EP2203176B1 (en) 2007-09-28 2014-11-26 Anthrogenesis Corporation Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
NZ591292A (en) 2008-08-20 2012-10-26 Anthrogenesis Corp Improved cell composition and methods of making the same
CA2734237C (en) 2008-08-20 2019-07-02 Anthrogenesis Corporation Treatment of stroke using isolated placental cells
SI2331109T1 (sl) 2008-08-22 2013-10-30 Anthrogenesis Corporation Postopki in sestavki za zdravljenje okvar kosti s populacijami placentarnih celic
WO2010059828A1 (en) 2008-11-19 2010-05-27 Anthrogenesis Corporation Amnion derived adherent cells
EP2449095A1 (en) 2009-07-02 2012-05-09 Anthrogenesis Corporation Method of producing erythrocytes without feeder cells
DK2454363T3 (da) * 2009-07-13 2020-10-12 Biogencell Ltd Fremgangsmåde til anvendelse af celler, der leder til specifik stam-/progenitorcelleaktivering og -differentiering
CA2787992A1 (en) 2010-01-26 2011-08-04 Anthrogenesis Corporation Treatment of bone-related cancers using placental stem cells
PL2556145T3 (pl) 2010-04-07 2017-02-28 Anthrogenesis Corporation Angiogeneza z zastosowaniem łożyskowych komórek macierzystych
KR20130092394A (ko) 2010-04-08 2013-08-20 안트로제네시스 코포레이션 태반 줄기 세포를 사용한 사르코이드증의 치료
MX342995B (es) 2010-07-13 2016-10-21 Anthrogenesis Corp Métodos de generar células asesinas naturales.
US8969315B2 (en) 2010-12-31 2015-03-03 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory RNA molecules
DK2714059T3 (en) 2011-06-01 2019-01-21 Celularity Inc TREATMENT OF PAIN WHEN USING PLACENT STAM CELLS
WO2013055476A1 (en) 2011-09-09 2013-04-18 Anthrogenesis Corporation Treatment of amyotrophic lateral sclerosis using placental stem cells
US8956870B2 (en) 2012-01-19 2015-02-17 Biogencell, Ltd. Method for using directing cells for specific stem/progenitor cell activation and differentiation
US9156897B2 (en) 2012-06-08 2015-10-13 Alkermes, Inc. Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
EP3622960A1 (en) 2013-02-05 2020-03-18 Celularity, Inc. Natural killer cells from placenta

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0676470A1 (en) * 1989-10-16 1995-10-11 Amgen Inc. Stem cell factor
HUT62011A (en) * 1989-10-16 1993-03-29 Amgen Inc Process for producing factors influencing the functioning of stem cells
US5635599A (en) * 1994-04-08 1997-06-03 The United States Of America As Represented By The Department Of Health And Human Services Fusion proteins comprising circularly permuted ligands
ATE299934T1 (de) * 1994-11-04 2005-08-15 Applied Research Systems Menschliche scf, eine spleissvariante davon,ihre pharmazeutische verwendung
BRPI9610977A2 (pt) * 1995-10-05 2019-09-17 Searle & Co agonistas receptores hematopoiéticos multi-funcionais
US5885962A (en) * 1996-04-05 1999-03-23 Amgen Inc. Stem cell factor analog compositions and method

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023145860A1 (ja) * 2022-01-27 2023-08-03 味の素株式会社 Ｓｃｆ受容体結合ペプチド

Also Published As

Publication number Publication date
AU734594B2 (en) 2001-06-21
AU4905797A (en) 1998-05-22
CA2268023A1 (en) 1998-05-07
WO1998018924A1 (en) 1998-05-07
EP0941321A1 (en) 1999-09-15
US5969105A (en) 1999-10-19

Similar Documents

Publication Publication Date Title
AU734594B2 (en) Circularly permuted polypeptides as novel stem cell factor receptor agonists
JP2001503266A (ja) 環状に並べ替えたエリスロポイエチン受容体アゴニスト
US6660257B1 (en) Circular permuteins of flt3 ligand
US6730303B1 (en) Fused G-CSF and IL-3 proteins and uses thereof
AU717733B2 (en) Novel G-CSF receptor agonists
KR100456212B1 (ko) 다기능성조혈수용체아고니스트
US6358505B1 (en) G-CSF receptor agonists
JP2001504689A (ja) 多機能性キメラ造血レセプターアゴニスト
WO1997012985A9 (en) Multi-functional hematopoietic receptor agonists
US6967092B1 (en) Multi-functional chimeric hematopoietic receptor agonists
AU722759B2 (en) Novel C-MPL receptor agonists
AU703627B2 (en) Interleuken-3 (IL-3) receptor agonists
JP2002515729A (ja) 新規ｇ−ｃｓｆ受容体アゴニスト
MXPA99003875A (en) NOVEL flt-3 RECEPTOR AGONISTS

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20041013

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20041013

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20070219